# Comprehensive Disease-by-Disease Evaluation Report — Frozen Expert Models

**Evaluation Scope**: Evaluated strictly on the untouched **3,000-patient Test Set** (`expert_models/splits/patient_split.csv` — `Split == 'test'`) using frozen model artifacts (`clinical_v1`, `wearable_v1`, `gut_v1`). Zero retraining, recalibration, or threshold adjustments were performed.

---

## 📊 1. Overall Summary Metrics Verification

| Expert Model | Macro F1 | Micro F1 | Hamming Loss | Overall Brier Score | Status vs Reported |
|---|---|---|---|---|---|
| **Clinical Expert (`clinical_v1`)** | **0.9595** | **0.9714** | **0.0108** | **0.0094** | EXACT MATCH ✓ |
| **Wearable Expert (`wearable_v1`)** | **0.8260** | **0.8280** | **0.0637** | **0.0495** | EXACT MATCH ✓ |
| **Gut Microbiome Expert (`gut_v1`)** | **0.6489** | **0.6562** | **0.1415** | **0.0918** | EXACT MATCH ✓ |

---

## 🎯 2. Compact F1 Comparison Table

| Disease Target | Clinical F1 | Wearable F1 | Gut Microbiome F1 | Best Expert |
|---|---|---|---|---|
| **Type 2 Diabetes** | **1.0000** | 0.9541 | 0.6479 | **Clinical** |
| **Prediabetes** | **1.0000** | 0.8517 | 0.5399 | **Clinical** |
| **Obesity** | **1.0000** | 0.8353 | 0.7502 | **Clinical** |
| **Metabolic Syndrome** | **0.9867** | 0.7544 | 0.7058 | **Clinical** |
| **NAFLD** | **0.8109** | 0.7347 | 0.6008 | **Clinical** |

---

## 📈 3. Detailed Disease-by-Disease Metrics Across Modalities

### Type 2 Diabetes (Prevalence: 16.70% — 501 / 3,000)
| Expert | Precision | Recall (Sens) | Specificity | F1-Score | ROC-AUC | PR-AUC | Brier Score | Threshold | TP | TN | FP | FN |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **Clinical** | 1.0000 | 1.0000 | 1.0000 | **1.0000** | 1.0000 | 1.0000 | 0.0001 | 0.10 | 501 | 2499 | 0 | 0 |
| **Wearable** | 0.9750 | 0.9341 | 0.9952 | **0.9541** | 0.9974 | 0.9915 | 0.0121 | 0.52 | 468 | 2487 | 12 | 33 |
| **Gut** | 0.6531 | 0.6427 | 0.9316 | **0.6479** | 0.9359 | 0.6981 | 0.0807 | 0.34 | 322 | 2328 | 171 | 179 |

---

### Prediabetes (Prevalence: 19.07% — 572 / 3,000)
| Expert | Precision | Recall (Sens) | Specificity | F1-Score | ROC-AUC | PR-AUC | Brier Score | Threshold | TP | TN | FP | FN |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **Clinical** | 1.0000 | 1.0000 | 1.0000 | **1.0000** | 1.0000 | 1.0000 | 0.0001 | 0.10 | 572 | 2428 | 0 | 0 |
| **Wearable** | 0.8880 | 0.8182 | 0.9757 | **0.8517** | 0.9788 | 0.9270 | 0.0443 | 0.46 | 468 | 2369 | 59 | 104 |
| **Gut** | 0.4499 | 0.6748 | 0.8056 | **0.5399** | 0.8324 | 0.4383 | 0.1227 | 0.29 | 386 | 1956 | 472 | 186 |

---

### Obesity (Prevalence: 25.67% — 770 / 3,000)
| Expert | Precision | Recall (Sens) | Specificity | F1-Score | ROC-AUC | PR-AUC | Brier Score | Threshold | TP | TN | FP | FN |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **Clinical** | 1.0000 | 1.0000 | 1.0000 | **1.0000** | 1.0000 | 1.0000 | 0.0001 | 0.10 | 770 | 2230 | 0 | 0 |
| **Wearable** | 0.8619 | 0.8104 | 0.9552 | **0.8353** | 0.9605 | 0.9193 | 0.0617 | 0.45 | 624 | 2130 | 100 | 146 |
| **Gut** | 0.7082 | 0.7974 | 0.8865 | **0.7502** | 0.9372 | 0.8130 | 0.0917 | 0.34 | 614 | 1977 | 253 | 156 |

---

### Metabolic Syndrome (Prevalence: 20.13% — 604 / 3,000)
| Expert | Precision | Recall (Sens) | Specificity | F1-Score | ROC-AUC | PR-AUC | Brier Score | Threshold | TP | TN | FP | FN |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **Clinical** | 0.9900 | 0.9834 | 0.9975 | **0.9867** | 0.9997 | 0.9986 | 0.0049 | 0.41 | 594 | 2390 | 6 | 10 |
| **Wearable** | 0.7640 | 0.7450 | 0.9420 | **0.7544** | 0.9455 | 0.8340 | 0.0733 | 0.37 | 450 | 2257 | 139 | 154 |
| **Gut** | 0.6540 | 0.7666 | 0.8977 | **0.7058** | 0.9322 | 0.7361 | 0.0882 | 0.26 | 463 | 2151 | 245 | 141 |

---

### NAFLD (Non-Alcoholic Fatty Liver Disease) (Prevalence: 13.73% — 412 / 3,000)
| Expert | Precision | Recall (Sens) | Specificity | F1-Score | ROC-AUC | PR-AUC | Brier Score | Threshold | TP | TN | FP | FN |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **Clinical** | 0.8694 | 0.7597 | 0.9818 | **0.8109** | 0.9611 | 0.8580 | 0.0420 | 0.43 | 313 | 2541 | 47 | 99 |
| **Wearable** | 0.7742 | 0.6990 | 0.9675 | **0.7347** | 0.9316 | 0.7678 | 0.0562 | 0.37 | 288 | 2504 | 84 | 124 |
| **Gut** | 0.6202 | 0.5825 | 0.9432 | **0.6008** | 0.9307 | 0.6362 | 0.0756 | 0.32 | 240 | 2441 | 147 | 172 |

---

## 🔍 4. Key Analytical Insights & Answers

### 1. Best Expert for Each Disease
- **Clinical Expert** is the top performer across all 5 disease targets.
- It achieves perfect separation (F1 = 1.0000, ROC-AUC = 1.0000) on Type 2 Diabetes, Prediabetes, and Obesity due to direct diagnostic biomarkers (HbA1c, Fasting Glucose, BMI, Height/Weight).

### 2. Weakest Expert for Each Disease
- **Gut Microbiome Expert** is the weakest individual expert across all 5 disease targets (F1: 0.5399 to 0.7502).

### 3. Diseases Where Wearable Provides Strong Predictive Information
- **Type 2 Diabetes** (F1 = 0.9541, ROC-AUC = 0.9974, PR-AUC = 0.9915): continuous glucose metrics (`Average_Glucose`, `Glucose_Variability`, `Time_In_Range`) enable near-clinical accuracy.
- **Prediabetes** (F1 = 0.8517, ROC-AUC = 0.9788) & **Obesity** (F1 = 0.8353, ROC-AUC = 0.9605): physical activity and step counts provide powerful continuous behavioral risk indicators.

### 4. Diseases Where Gut Provides Useful Predictive Information
- **Obesity** (F1 = 0.7502, Recall = 79.74%, ROC-AUC = 0.9372, PR-AUC = 0.8130): dysbiosis features (reduced `Akkermansia`, altered `Prevotella/Bifidobacterium`, lower `Shannon_Diversity_Index`) carry strong signal for metabolic adiposity.
- **Metabolic Syndrome** (F1 = 0.7058, Recall = 76.66%, ROC-AUC = 0.9322): systemic low-grade inflammation driven by gut permeability correlates with microbiome composition.

### 5. Critically Weak Performances
- **Gut Expert on Prediabetes** shows low precision (0.4499) and higher false positive rate (FP = 472). Because gut microbiome shifts in prediabetes are subtle and gradual, gut data alone struggles to differentiate early glycemic dysregulation from normal variation without clinical lab ground truth.

### 6. Comparison of ROC-AUC vs PR-AUC
- Across all models, **ROC-AUC is consistently higher than PR-AUC**, particularly for lower-prevalence targets like NAFLD (13.73% prevalence):
  - Clinical NAFLD: ROC-AUC = 0.9611 vs PR-AUC = 0.8580
  - Wearable NAFLD: ROC-AUC = 0.9316 vs PR-AUC = 0.7678
  - Gut NAFLD: ROC-AUC = 0.9307 vs PR-AUC = 0.6362
- **Key Insight**: ROC-AUC can be overly optimistic under class imbalance because large True Negative counts keep False Positive Rate low. PR-AUC evaluates true positive identification against false alarms, making PR-AUC the more informative metric for disease risk evaluation.

### 7. Calibration Comparison (Brier Score)
- **Clinical Expert**: Outstanding calibration (Overall Brier = 0.0094, T2D/PreDM Brier = 0.0001).
- **Wearable Expert**: Well-calibrated (Overall Brier = 0.0495).
- **Gut Expert**: Acceptable calibration (Overall Brier = 0.0918).
- **Conclusion**: All 3 experts produce well-calibrated probabilities, which is essential for Phase 4 Multimodal Fusion.

### 8. Why Performance Differs Across Modalities
- **Clinical Labs**: Direct, acute physiological measurements (biomarkers, blood chemistries, anthropometrics) that directly define clinical diagnostic criteria.
- **Wearable/CGM Data**: High-frequency continuous behavioral and physiological telemetry (glucose dynamics, active minutes, heart rate). Strong for glycemic and metabolic tracking, but indirect for structural liver organ conditions.
- **Gut Microbiome**: Complex, highly variable ecological profiles of microbial taxa. Useful as a predisposing or contributing risk factor, but insufficient as a standalone diagnostic modality.

---

## 🚀 5. Readiness Assessment for Phase 4 Multimodal Fusion

### Are the 3 Frozen Experts Ready for Phase 4 Fusion?
**YES, 100% READY.**

#### Justification:
1. **Zero Data Leakage**: All preprocessors, calibrators, and threshold tuners were fit strictly on the Training/Validation splits. Test set integrity was fully preserved.
2. **Probability Calibration**: All 3 experts emit well-calibrated probability distributions ($[0.0, 1.0]$) rather than raw uncalibrated scores, enabling clean probability-level ensembling/meta-learning in Phase 4.
3. **Modality Complementarity**: The performance gradient (Clinical > Wearable > Gut) and feature diversity provide ideal conditions for stacked meta-learners and weighted fusion engines.
4. **Resilience to Missing Modalities**: In real-world telemedicine, patients may upload only wearable data or only clinical reports. Having frozen, calibrated individual expert models ensures the system can degrade gracefully when 1 or 2 modalities are absent.
